Astrazeneca Pharma India Ltd

Stage 4 · Declining · week 13

As of 16 Oct 2026, Astrazeneca Pharma India is in Stage 4 — declining, a downtrend, in week 13 (since 20 Jul 2026). It closed at ₹5,971, 39.2% below its 52-week high and below its 200-day average, which is falling. In Health Care, 40.6% of stocks are in Stage 2.

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. More about the company

₹5,970.5
+0.56% today
₹14,926 Cr · Mid cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dPharmaceuticals 50.4%-2.5 pts

Pro read

Pro

Our read

Declining — below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ASTRAZEN early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-39.2%
₹5,719.5 lo₹9,827.5 hi
39.2% below 52W high — deep Stage 4 damage
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 13
1w13w26w
Week 13 — established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-25.7%
200 DMA: ₹8,040.5 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
0.87x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↓
MA20 rolling over · -6.9% vs MA50 -10.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-10.9%
3M
-25.6%
6M
-30.0%
YTD
-34.6%
1Y
-35.6%
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.4%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 36w
S2 27w
S2 28w
S4 21w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 36w → S3 9w → S2 27w → S3 9w → S2 28w → S3 8w → S2 10w → S3 3w → S4 21w → S1 5w → S4 13w current
Total tracked: 169 weeks across 11 stage runs.
Scan Membership
Breakout Watch
Latest: 2025-10-23
3 appearances in last 60 days. First seen: 2024-05-28.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S4
Wk 13 · Vol 0.87x
2026-10-15S4
Wk 13 · Vol 1.09x
2026-10-14S4
Wk 13 · Vol 1.07x
2026-10-13S4
Wk 12 · Vol 3.26x
2026-10-12S4
Wk 12 · Vol 0.31x
2026-10-09S4
Wk 12 · Vol 0.68x
2026-10-08S4
Wk 12 · Vol 0.52x
2026-10-07S4
Wk 12 · Vol 0.47x
2026-10-06S4
Wk 11 · Vol 0.43x
2026-10-05S4
Wk 11 · Vol 0.48x
2026-10-01S4
Wk 11 · Vol 0.88x
2026-09-30S4
Wk 11 · Vol 4.72x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹6,836.7
200 DMA
₹8,040.5
52W High
₹9,827.5
52W Low
₹5,719.5
5D Low
₹5,877.5
Resistance levels (recent highs)
20d High
₹6,751.5
60d High
₹8,300
120d High
₹8,962.5
250d High
₹9,827.5
Next resistance
+13.1%
to 20d High
Ask the Market AI about ASTRAZENAsk →
P/E (TTM)
107.2
Forward —
Earnings Growth (YoY)
-23.0%
Revenue +21.7%
ROE
+22.8%
Profit margin +8.1%
Dividend Yield
0.36%
P/B 27.1
About this companyHealth Care· Pharmaceuticals

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.